[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"biomarker:swi-snf-related-matrix-associated-actin-dependent-regulator-of-chromatin-subfamily-b-member-1":3},{"name":4,"total":5,"recruiting":6,"trials":7},"SWI\u002FSNF-Related Matrix-Associated Actin-Dependent Regulator of Chromatin Subfamily B Member 1",5,4,[8,16,23,29,36],{"nct_id":9,"title":10,"phases":11,"status":13,"updated_at":14,"content_modified":15},"NCT05687136","Testing the Combination of Two Anti-cancer Drugs, Peposertib (M3814) and Tuvusertib (M1774) for Advanced Solid Tumors",[12],"Phase 1","RECRUITING","2026-08-26T02:17:30.145302Z","2026-07-05T05:32:16.811559Z",{"nct_id":17,"title":18,"phases":19,"status":13,"updated_at":21,"content_modified":22},"NCT07447076","Study of Novel Therapies for Young People With Recurrent\u002FProgressive Atypical Teratoid Rhabdoid Tumor (ATRT)",[20],"Phase 2","2026-08-26T02:15:36.077529Z","2026-05-05T02:43:29.727119Z",{"nct_id":24,"title":25,"phases":26,"status":13,"updated_at":27,"content_modified":28},"NCT06444880","Phase II Trial of Ubamatamab Alone or in Combination With Cemiplimab in MUC16-Expressing SMARCB1-Deficient Malignancies",[20],"2026-08-03T03:45:11.273644Z","2026-05-05T02:43:27.586903Z",{"nct_id":30,"title":31,"phases":32,"status":13,"updated_at":34,"content_modified":35},"NCT04390737","Evaluate the Safety and Clinical Activity of HH2853",[33],"Phase 1\u002FPhase 2","2026-08-26T02:18:54.586325Z","2026-05-05T02:43:26.959800Z",{"nct_id":37,"title":38,"phases":39,"status":40,"updated_at":41,"content_modified":42},"NCT07438626","Phase II Trial of Sacituzumab Tirumotecan in Patients With SMARCB1-Deficient Renal Medullary Carcinoma",[20],"NOT_YET_RECRUITING","2026-08-26T02:16:33.772093Z","2026-05-05T02:43:27.396122Z"]